Excaliard Pharmaceuticals announced results from three Phase 2 clinical trials of EXC 001 in skin scarring. The three studies demonstrated EXC 001’s efficacy in elective revision surgery of scars resulting from prior breast surgery (Study 203), efficacy in fine line scars in elective abdominoplasty surgery (Study 202) and activity in a biomarker study of abdominal scars (Study 201). The results showed a significant reduction in scar severity for EXC 001 treated scars versus placebo treated scars in all three trials. EXC 001 was well tolerated with no important drug related adverse effects observed.
EXC 001 is an antisense oligonucleotide designed to interrupt the process of fibrosis by inhibiting expression of connective tissue growth factor (CTGF).
For more information call (760) 431-1850 or visit www.excaliard.com.